RESEARCHER PROFILE

Gerhard Ehninger

← Back to Technische Universität Dresden

G

Technische Universität Dresden

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationRetinoids in leukemia and cellular processesChronic Myeloid Leukemia TreatmentsTransplantation: Methods and Outcomes

Gerhard Ehninger works in Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Retinoids in leukemia and cellular processes, Chronic Myeloid Leukemia Treatments, Transplantation: Methods and Outcomes. Recorded institutional associations include University Hospital Carl Gustav Carus, Technische Universität Dresden.

1,205Publications
49,532Citations
104H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    2017 · 2,227 citations
  2. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    2002 · 1,735 citations
  3. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    2013 · 1,612 citations
  4. Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro

    2004 · 1,317 citations
  5. Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

    2012 · 920 citations
  6. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)

    2006 · 736 citations
  7. Acute myeloid leukaemia

    2016 · 592 citations
  8. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN)

    2020 · 555 citations
  9. Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

    2007 · 516 citations
  10. Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

    2010 · 500 citations
  11. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

    1995 · 465 citations
  12. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    2015 · 401 citations
  13. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

    2011 · 389 citations
  14. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

    2016 · 389 citations
  15. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

    2014 · 378 citations
  16. Rapamycin extends murine lifespan but has limited effects on aging

    2013 · 373 citations
  17. Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

    2004 · 356 citations
  18. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

    2014 · 355 citations
  19. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

    2017 · 351 citations
  20. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

    2018 · 345 citations
  21. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

    2012 · 341 citations
  22. Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

    2013 · 313 citations
  23. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

    2004 · 307 citations
  24. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

    2008 · 306 citations
  25. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

    2010 · 304 citations

← Return to the university profile